Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations
Authors (first, second and last of 31)
Collection
Genome Editing and the Future of Personalized and Targeted Cancer Medicine
Many human diseases, including cancer, have their etiology in genome alterations. Completion of the human genome project and the development of next generation sequencing technologies with single cell resolution will lead to routine complete genome mapping of cancer patients in the future. Genome editing is based on unique properties shared by mega-nucleases, zinc-finger nucleases, transcription activator-like effector nucleases, and the CRISPR/Cas9 system and their ability to generate cuts in the human genome at specific targeted sites thereby allowing replacement of defective DNA with a corrected sequence. Although still in its infancy, these technologies have the potential to revolutionize medicine and patient care.
Molecular Cancer is excited to present a series of original research and review articles related to genome editing and reprogramming.
Articles (22 in this collection)
-
-
Targeting CRAF kinase in anti-cancer therapy: progress and opportunities
Authors (first, second and last of 5)
-
A positive feedback circuit driven by m6A-modified circular RNA facilitates colorectal cancer liver metastasis
Authors (first, second and last of 10)
-
circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma
Authors (first, second and last of 10)
-
Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches
Authors (first, second and last of 10)
-
Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells
Authors (first, second and last of 7)
-
Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo
Authors (first, second and last of 21)
-
-
Enhancement of TKI sensitivity in lung adenocarcinoma through m6A-dependent translational repression of Wnt signaling by circ-FBXW7
Authors (first, second and last of 14)
-
A novel protein encoded by circINSIG1 reprograms cholesterol metabolism by promoting the ubiquitin-dependent degradation of INSIG1 in colorectal cancer
Authors (first, second and last of 12)
-
Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
Authors (first, second and last of 17)
-
Minimally invasive approaches for the early detection of endometrial cancer
Authors (first, second and last of 4)
-
LncRNA-BC069792 suppresses tumor progression by targeting KCNQ4 in breast cancer
Authors (first, second and last of 12)
-
Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy
Authors (first, second and last of 13)
-
Biological and pharmacological roles of m6A modifications in cancer drug resistance
Authors (first, second and last of 10)
-
Antioxidants in brain tumors: current therapeutic significance and future prospects
Authors (first, second and last of 10)
-
Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma
Authors (first, second and last of 18)
-
Monitoring autochthonous lung tumors induced by somatic CRISPR gene editing in mice using a secreted luciferase
Authors (first, second and last of 18)
-
The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy
Authors (first, second and last of 12)
-
PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma
Authors (first, second and last of 40)
-
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Authors (first, second and last of 8)
-
MARCKSL1–2 reverses docetaxel-resistance of lung adenocarcinoma cells by recruiting SUZ12 to suppress HDAC1 and elevate miR-200b
Authors (first, second and last of 10)
